Indeed, anti‐VEGF, when given systemically; intravenously, vascular‐related complications, namely hypertension, myocardial infarction, thromboembolic events and stroke have been identified (Avery et al., 2014; Chen & Cleck, 2009; Kamba & McDonald, 2007). This evidence concerns the gene VEGFA and hypertensive disorder.